NCT00724334View on ClinicalTrials.gov

A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Myelofibrosis
Interventions
DRUG

SAR302503 (TG101348)

orally administered, once a day

Trial Locations (6)

55905

Investigational Site Number 840104, Rochester

77030

Investigational Site Number 840101, Houston

92093

Investigational Site Number 840103, La Jolla

94305

Investigational Site Number 840102, Stanford

02115

Investigational Site Number 840105, Boston

48109-0759

Investigational Site Number 840106, Ann Arbor

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT00724334 - A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis | Biotech Hunter | Biotech Hunter